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Abstract
Rationale: Expanding the use of cystic fibrosis transmembrane
conductance regulator (CFTR) potentiators and correctors for the
treatment of cystic fibrosis (CF) requires precise and accurate
biomarkers. Sweat chloride concentration provides an in vivo
assessment of CFTR function, but it is unknown the degree to which
CFTRmutations account for sweat chloride variation.
Objectives: To estimate potential sources of variation for sweat
chloride measurements, including demographic factors, testing
variability, recording biases, and CFTR genotype itself.
Methods: A total of 2,639 sweat chloride measurements were
obtained in 1,761 twins/siblings from the CF Twin-Sibling Study,
French CF Modifier Gene Study, and Canadian Consortium for
Genetic Studies. Variance component estimation was performed by
nested mixed modeling.
Measurements and Main Results: Across the tested CF
population as a whole, CFTR gene mutations were found to be the
primary determinant of sweat chloride variability (56.1% of
variation) with contributions from variation over time (e.g., factors
related to testing on different days; 13.8%), environmental factors
(e.g., climate, family diet; 13.5%), other residual factors (e.g., test
variability; 9.9%), and unique individual factors (e.g., modifier
genes, unique exposures; 6.8%) (likelihood ratio test, P, 0.001).
Twin analysis suggested that modifier genes did not play a
significant role because the heritability estimate was negligible
(H2 = 0; 95% confidence interval, 0.0–0.35). For an individual with
CF, variation in sweat chloride was primarily caused by variation
over time (58.1%) with the remainder attributable to residual/
random factors (41.9%).
Conclusions:Variation in the CFTR gene is the predominant cause
of sweat chloride variation;most of the non-CFTR variation is caused
by testing variability and unique environmental factors. If test
precision and accuracy can be improved, sweat chloride
measurement could be a valuable biomarker for assessing response
to therapies directed at mutant CFTR.
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Cystic fibrosis (CF) is a monogenic
autosomal-recessive life-shortening
disorder affecting about 70,000 individuals
worldwide. The disorder is caused by
dysfunction of the CF transmembrane
conductance regulator (CFTR), which is a
cAMP-regulated chloride and bicarbonate
channel (1, 2). Loss of CFTR function in the
sweat gland leads to an elevation in chloride
concentration. In the epithelia of the lungs
and pancreas, CFTR dysfunction causes
aberrant ion and water movement leading
to obstruction and eventual destruction of
both organ systems (3). Recent success in
augmenting the function of CFTR bearing
some of the most common mutations has
energized efforts to develop molecular
therapies for all disease-causing variants (4, 5).
The U.S. Food and Drug
Administration–approved indications for
use of the CFTR potentiator ivacaftor
(Kalydeco) and the combination of
ivacaftor and a CFTR corrector lumacaftor
(Orkambi) (6) includes 11 CFTR mutations
(7) that encompass approximately 60% of
all individuals with CF. Expanding the use
of CFTR-targeted drugs to all patients with
CF is challenging for several reasons. First,
the remaining 40% of affected individuals
carry at least 1,700 different CFTR
mutations (8). Many of these mutations
occur in one or only a few individuals with
CF. Thus, traditional clinical trials that
enroll sufficient numbers of subjects to
reveal statistically significant differences
among treatment groups will be difficult to
conduct. Second, accurate biomarkers are
needed for measuring CFTR function,
because small molecule therapies may not
provide an equivalent clinical improvement
for all CFTR mutations. Lung function is an
important endpoint measure because it is
the primary cause of morbidity and is
correlated with survival in CF (9). However,
considerable variability in lung function
measures occurs among patients of the
same age and bearing the same CFTR
mutations (10–12). The substantial
variation is caused by contributions both
from modifier genes and environmental
factors (13, 14), thus making lung function
an imprecise measure of CFTR function.
This may be reflected in studies of CFTR-
targeted drugs where lung function (FEV1)
is not tightly correlated with other
measures of CFTR function, specifically
sweat chloride measurements (4, 15–17).
The chloride concentration in sweat could
serve as a useful biomarker of CFTR function
in vivo in assessing the response to molecular
treatments (18). Indeed, prior research studies
have shown correlation between functional
classes of CFTR variants and sweat chloride
concentration (19, 20). In clinical use, patients
suspected to have CF typically receive the
test for diagnostic purposes at the time of
initial presentation. Serial sweat chloride
measurements can be used to follow the
effects of therapies directly affecting CFTR
function (4, 16, 17, 21); however, there is an
incomplete understanding of the causes of
variation in this measure (15, 22). We sought
to estimate potential sources of variation for
sweat chloride measurements, including
demographic factors, testing variability,
recording biases, and CFTR genotype itself.
The twins and siblings affected with CF
also allowed estimating the contribution
of genetic modifiers to sweat chloride
measurement variability. Some of these
results have been previously reported in
the form of an abstract (23).
Methods
Study Sample
The primary population for this study
(Table 1) included 1,761 subjects with CF,
including 1,697 twins and siblings from the
CF Twin-Sibling Study, 40 twins from the
French CF Modifier Gene Study, and 24
twins from the Canadian Consortium for
Genetic Studies. Written consent was
obtained from all subjects and this study
was approved by the Johns Hopkins
University Institutional Review Board
(Protocol NA–00035659). In addition, sex
and age effects were assessed in an
independent population of unrelated
individuals with CF and homozygous for
the most common CFTR mutation,
Phe508del (n = 1,191), recruited for the
Genetic Modifier Study at the University
of North Carolina and Case Western
Reserve University (24).
Demographics
Race/ethnicity was self-reported in the CF
Twin-Sibling Study only with subjects
with any nonwhite ancestry defined as
nonwhite. Exocrine pancreatic
sufficiency, a common manifestation of
CFTR dysfunction, was defined by
genotype for 1,592 subjects (90.4% of
subjects) as being sufficient with one or
more “pancreatic sufficient” mutations or
being insufficient with two “insufficient”
mutations, and by clinical data for 149
subjects (8.5%) where genotype data
was indeterminate or not available. The
“sufficiency” of mutations was based
on CFTR2 population level data for
mutations (www.cftr2.org) (25, 26). For
20 subjects (1.1%) pancreatic status was
unable to be determined.
Sweat Chloride Measurements
A total of 2,678 sweat chloride
measurements (mmol/L) obtained by
pilocarpine iontophoresis were extracted
from clinical records. Data for subjects
in the CF Twin-Sibling Study were
supplemented with data obtained from
the U.S. CF Foundation Patient Registry.
Published guidelines state that sweat
chloride measurements greater than
150–160 mmol/L are not physiologically
compatible (27–29); 39 measurements
greater than 145 mmol/L were dropped.
Minimum, mean, and maximum values
were based on all available measurements
from an individual.
Statistical Analysis
The contribution of CFTR genotype to
sweat chloride variation was estimated
using a nested-factor mixed model for
At a Glance Commentary
Scientific Knowledge on the
Subject: Expanding the use of cystic
fibrosis transmembrane conductance
regulator (CFTR) potentiators and
correctors for the treatment of cystic
fibrosis requires precise and accurate
biomarkers. Sweat chloride concentration
provides an in vivo assessment of
CFTR function, but the degree to which
CFTR mutations account for sweat
chloride variation is unknown.
What This Study Adds to the
Field: We found that variation in the
CFTR gene is the predominant cause
of sweat chloride variation; most of the
non-CFTR variation is caused by
testing variability and unique
environmental factors. If test precision
and accuracy can be improved, sweat
chloride measurement could be a
valuable biomarker for assessing
response to therapies directed at
mutant CFTR.
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variance component estimation with
all available measurements (STATA
command xtmixed with REML option;
StataCorp LP, College Station, TX) (30).
In our model, measurements by testing
date were nested inside individuals, who
in turn were nested inside families, which
in turn were nested inside CFTR genotypes.
The mixed model was limited to subjects
with at least one Phe508del mutation; CFTR
genotype groups for this model were
assigned by the non-Phe508del mutation for
Phe508del heterozygotes and into a single
group for Phe508del homozygotes. For
heritability calculations, the maximum sweat
chloride measurement for an individual was
used for subjects who had more than one
measurement recorded. Heritability was
estimated by calculating the Pearson
correlation coefficients for sweat chloride
measurements for monozygous (MZ) twins,
dizygous (DZ) twins, and siblings, then
subtracting the coefficient for DZ twins
(or siblings) from the coefficient for MZ
twins, and multiplying the difference by 2
(31). Heritability estimates less than 0 and
greater than 1.0 were reported as 0 and
1, respectively. Heritability confidence
intervals were estimated by bootstrapping
(32). The effects of age on sweat chloride
were also assessed using linear regression
clustered by family; subjects without a
documented age at the time of testing
(n = 14) were excluded from age-adjusted
analyses. Families with discordant CFTR
genotypes were not used for heritability
or mixed model analyses. Linearity assumptions
were assessed as part of the modeling
process. Analyses were performed using
Stata IC 11.0 (StataCorp LP, College
Station, TX).
Results
Demographics
A total of 2,639 measurements were
available for analysis for 1,761 subjects in
the primary population, including one
measurement only for 1,073 subjects, two
measurements for 552 subjects, three for 91
subjects, four for 38 subjects, five for five
subjects, and six for two subjects. The
average maximum sweat chloride values
for subjects who had more than one test
recorded (98.66 20.0 mmol/L; n = 688)
were not different than the sweat chloride
measurement for those subjects who only
had a single test recorded (97.46 19.7
mmol/L; n = 1073; P = 0.18) (Figure 1).
However, for those who had more than
one test recorded, the averages of their
mean values (93.06 19.7; P, 0.001) and
minimum values (87.46 21.7; P, 0.001)
were different than the single value for
those who had only one test recorded.
The differences indicated a bias toward
the maximum value being recorded,
likely caused by healthcare providers
preferentially entering the highest sweat
chloride value when multiple tests had been
performed. To address this bias, only the
maximum sweat chloride value for each
subject was used for the analyses that follow,
except the mixed model where all values were
used to estimate the contribution of testing
variability. The average of the maximum
sweat chloride values for all 1,761 subjects
was 97.96 19.8 mmol/L (range, 11.0–145.0).
The mean age of testing was 3.26 6.2 years
(range, 0–52.9; n = 1,747) for subjects with
data available.
Age Influences Sweat Chloride
Measurements
We first wished to ascertain if age, sex, or
race/ethnicity played a role in sweat chloride
variation, so as to adjust for these factors if
appropriate. To exclude variation caused
by CFTR, we restricted these analyses to
the largest group of subjects with an
identical CFTR genotype (822 individuals
homozygous for the most common CFTR
mutation [Phe508del]). Maximum sweat
chloride values per individual were
Table 1. Demographics
Study Population (N = 1,761)
Sex, % female (n = 1,731) 48.0
Race/ethnicity, % white (n = 1,695) 90.3
Age as of 12/31/2011, yr, mean6 SD 19.86 10.3
Age at diagnosis, yr (n = 1,697)
Mean6 SD 2.366 5.33
Median 0.33
IQR 0.08–2.03
CFTR genotype, % (n = 1,755)
0 Phe508del mutations 10.7
1 Phe508del mutations 42.5
2 Phe508del mutations 46.8
Pancreatic status, % insufficient (n = 1,741) 85.1
Definition of abbreviations: CFTR = cystic fibrosis transmembrane conductance regulator;
IQR = interquartile range.
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Figure 1. Maximum, mean, and minimum sweat chloride values by number of tests performed for
a subject. The average maximum value for subjects with more than one measurement was not
different than the average measurement for subjects with only one measurement as opposed to
the average mean or minimum values for subjects with more than one measurement, thus illustrating
a potential bias to record maximum measurements preferentially.
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normally distributed around a mean of
101.36 14.9 mmol/L, illustrating the
variability of measurements, even among
individuals with identical CFTR genotypes
(Figure 2).
Using regression, increasing sweat
chloride values were associated with
increasing age (n = 817 Phe508del
homozygotes; P = 0.001). The average
maximum sweat chloride value was 99.26
14.8 mmol/L for subjects between 0 and 1
year of age at the time of testing (n = 549),
102.56 12.6 mmol/L between 1 and 2 years
of age (n = 76), 105.76 15.4 mmol/L
between 2 and 3 years of age (n = 49), and
106.96 14.9 mmol/L for subjects 3 or more
years of age (n = 143) (Figure 3; see Figure
E1 in the online supplement). However,
because 90% of these subjects are less than
5 years of age, the relationship between
sweat chloride values and age may not be
linear at older ages. We also evaluated
effects of age on sweat chloride on an
independent population of subjects from
the Gene Modifier Study who were
Phe508del homozygotes. The mean sweat
chloride value was 102.16 15.0 mmol/L for
subjects between 0 and 1 year of age at the
time of testing (n = 392), 100.76 14.6
mmol/L between 1 and 2 years of age
(n = 275), 105.36 15.5 mmol/L between
2 and 3 years of age (n = 107), and
106.46 14.8 mmol/L for subjects 3 or more
years of age (n = 417), which were
comparable with data from the primary
population. To address age-related changes
for heritability estimates in comparing
twins or siblings who may have been
different ages at the time of testing, all
sweat chloride results obtained between
0 and 1 years of age were adjusted upward
by 7.7 mmol/L, those between 1 and 2 years
of age were adjusted by 4.4 mmol/L, and
those obtained between 2 and 3 years of age
were adjusted by 1.2 mmol/L (33).
There were no differences in maximum
sweat chloride values by sex (n = 785;
P = 0.72) or by race/ethnicity (n = 783;
P = 0.97). However, some evidence of
differences between males and females in
older children and adults homozygous for
the Phe508del mutation was noted. In a
subpopulation of Phe508del homozygotes
over 2 years of age, males tended to have a
higher sweat chloride measurement
(108.46 16.2 mmol/L; n = 113) than
females (105.16 12.8 mmol/L; n = 83;
P = 0.12). We saw a similar trend in the
Gene Modifier Study (Phe508del
homozygotes aged 2 yr or older at the time
of testing) toward higher sweat chlorides in
males (107.16 15.0 mmol/L; n = 277)
compared with females (105.26 14.8 mmol/L;
n = 247) (Student’s t test, P= 0.15). Although a
meta-analysis incorporating both datasets
indicates that males older than 2 years of
age have a higher mean sweat chloride than
females (P = 0.042), we did not adjust our
data for sex because there was no significant
difference in the primary population.
CFTR Genotype Is the Predominant
Determinant of Sweat Chloride
Concentration in the CF Population
To quantify the relative contribution of
CFTR mutations, and other genetic and
environmental factors to sweat chloride
variation, we performed variance components
estimation using a nested mixed model. A
total of 2,160 age-adjusted sweat chloride
measurements from 1,489 subjects were nested
into 832 families, which were nested into 111
CFTR genotype groups. Based on the variance
of sweat chloride at each nested level, we
estimated that over half of the variation
(56.1%) in sweat chloride measurements
was attributable to variation in CFTR
genotype (likelihood ratio test, P, 0.001)
(Table 2). A further 13.5% and 6.8% were
attributable to common or shared genetic/
environmental factors within a family (e.g.,
climate, familial diet, intragenic CFTR
modifiers) and factors unique to an
individual (e.g., modifier genes, unique
exposures), respectively. The remaining
contributions to sweat chloride variation
were accounted for by variability within
an individual over time because of testing
on different days (but not age, which was
adjusted for; 13.8%) and mixed model
residual variation caused by differences
in testing performed on the same day
(9.9%). Finally, repeating the model with
only a single sweat chloride measurement
per subject (maximum) yielded a similar
estimate of the variation caused by CFTR
(59.0%).
Biologic Variability, Testing
Variability, and Other
Residual/Random Factors in
Individuals with CF
The use of sweat chloride as a biomarker
for response to pharmaceutical agents is
enhanced with the knowledge of the factors
that influence measurements in an
individual between time intervals. From our
mixed model, we estimated that 58.1% of
variance in sweat chloride measurements in
an individual (proportion of variance from
Table 2 = 80.5/[80.51 58.1]) would be
secondary to variation over time (e.g.,
dietary changes or testing variability over
time), and 41.9% of variance (proportion of
variance from Table 2 = 58.1/[80.51 58.1])
N = 822; Mean = 101.3; S.D.= 14.9
0
50
100
150
N
u
m
be
r 
of
 
Su
bje
ct
s
50 75 100 125 150
Sweat Chloride Concentration (mmol/L)
Figure 2. Histogram for maximum sweat chloride values in subjects with the same cystic fibrosis
transmembrane conductance regulator (CFTR) mutations (Phe508del homozygotes), illustrating the
variability present in sweat chloride measurements even within the same CFTR genotype.
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would be secondary to testing variability
and/or other residual/random factors.
To confirm our estimates of testing
variability obtained from the mixed model,
we examined variability in subjects who had
two or more sweat chloride measurements
recorded on the same calendar day.
Presumably these measurements were
obtained at the same CF center by the same
tester, thereby controlling for differences in
operator and equipment. In our population,
393 subjects had more than one value
recorded on the same day on a total of 405
separate days. The mean difference between
the maximum and minimum recorded
values for a subject for testing performed on
the same day was 7.16 9.6 mmol/L,
which is similar to the SD estimate obtained
from the mixed model (7.6 mmol/L).
Interestingly, we found testing variability to
have decreased with time, which may be
caused by guidelines promoting uniform
procedures and interpretation (27, 34, 35),
but it is less clear whether changes in
testing techniques have contributed to
this (36, 37). The mean difference was
11.5 mmol/L in the period 1968–1979
(n = 28), 7.6 between 1980 and 1989 (n = 81),
7.2 between 1990 and 1999 (n = 184), and
5.7 between 2000 and 2009 (n = 112). Also,
we found no difference in sweat chloride
measurements by season when comparing
those obtained in winter months with
those obtained during summer months
(P = 0.48; n = 1,284 measurements).
Non-CFTR Modifier Genes Contribute
Minimally to Variation in Sweat
Chloride Concentration
To estimate the contribution of modifier
genes versus unique environmental factors
to variation in sweat chloride values, we
performed heritability analyses. Within
the 1,761 individuals with sweat chloride
measurements, there were 730 family-based
pairs after exclusions (Figure 4). In families
with more than two members with sweat
chloride tests, we only included one pair
of subjects for each family to avoid
overrepresentation of these families; the
chosen pairs were the two siblings closest in
age to minimize cohort effects. MZ twins
who share 100% of their DNA variants
demonstrated a high degree of correlation
(r = 0.83; n = 96 pairs). Sweat chloride
correlation was also very similar in DZ
twins who share only 50% of their genetic
variation on average (r = 0.87; n = 30 pairs).
The similar degree of correlation in MZ and
DZ twin pairs indicated that modifier genes
did not contribute substantially to variation
in sweat chloride concentration (estimated
heritability or H2 = 0; 95% confidence
interval, 0.0–0.35) (Table 3).
Because the degree of correlation
among DZ twins exceeded that which could
be attributed to sharing of genetic factors
(e.g., r. 0.50 [50%]), we predicted that
environmental factors common to twin pairs
(e.g., testing center, diet) play an important
role. To test this possibility, intrapair
correlations of siblings and DZ twins were
used to estimate effect of environment
because both classes share 50% of their
genetic variation, but siblings born at
different times have greater differences in
environmental exposures. Indeed, correlation
among 604 sibling pairs (r = 0.52) was lower
than observed in 30 DZ pairs (r = 0.87; P,
0.001) reflecting greater differences in
environment between siblings than between
DZ siblings. One key difference is that
siblings are more likely to be tested under
different circumstances (i.e., test facility, date)
than DZ twins. In support of this supposition,
when analysis was restricted to eight sibling
pairs whose tests were conducted on the same
day (which eliminates testing variability over
different dates), the intrapair correlation
increased (r = 0.79) and was not different
than 16 pairs of DZ twins with tests
conducted on the same day (r = 0.90;
P = 0.67). Finally, to assess whether
heritability estimation was confounded by
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Figure 3. Maximum sweat chloride values by age with Lowess-smoothed line illustrating an increase
in sweat chloride measurements with age. (A) Data for Phe508del homozygotes only who were
,5 years old at the testing. (B) Data for Phe508del homozygotes only regardless of age.
Table 2. Sources of Variance in Sweat Chloride Measurements in a Mixed Model*
Nested Level Potential Sources of Variation
Sweat Chloride SD
Estimate (95% CI)†
Sweat Chloride
Variance Estimate
(95% CI)
Percentage of
Variance
CFTR genotype CFTR genotype 18.1 (15.1–21.7) 328.2 (229.1–470.3) 56.1
Family Common environment and intragenic
CFTR modifiers
8.9 (7.8–10.0) 78.7 (61.3–101.0) 13.5
Individual Genetic modifiers and unique environment 6.3 (4.7–8.3) 39.5 (22.5–69.3) 6.8
Date of testing Biological variability over time 9.0 (7.9–10.2) 80.5 (62.5–103.6) 13.8
Mixed model residual Testing variability and residual/random factors 7.6 (7.1–8.2) 58.0 (50.6–66.6) 9.9
Definition of abbreviations: CFTR = cystic fibrosis transmembrane conductance regulator; CI = confidence interval.
*For this mixed model a total of 2,160 age-adjusted sweat chloride measurements obtained from 1,489 subjects were nested into 832 families, which
were nested into 111 CFTR genotype groups.
†The mean sweat chloride (intercept) estimated by the model was 95.6 mmol/L (95% CI, 91.8–99.5).
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interaction with CFTR, we conducted a
subanalysis on subjects with the same CFTR
genotype (Phe508del homozygotes). In this
subpopulation the correlation was almost
identical between MZ (r = 0.65; n = 58 pairs)
and DZ twins (r = 0.64; n = 16 pairs), also
yielding a low estimate of heritability.
Discussion
The Role of CFTR
Identifying sources of variation in traits,
such as sweat chloride, whichmay be used to
determine the efficacy of CFTR-targeted
therapies, is critically important to deliver
the right care to the right patient and to
assess its effects accurately. Our study results
indicate that most variation in sweat
chloride measurements relates to CFTR
genotype (56.1%). This confirms previous
work demonstrating significant variation
in sweat chloride measurements between
different classes of CFTR mutations
(19, 20). However, subjects with the same
CFTR genotype (Phe508del homozygotes)
still exhibit considerable variation in sweat
chloride measurements. We did not find
evidence of substantial contribution of
non-CFTR modifier genes. The remaining
variability in sweat chloride is attributed
to environmental and residual/random
factors, including testing variability.
Identifying and controlling any contributory
environmental factors could improve the
precision and accuracy of the sweat chloride
test, thus improving the utility of this
measure as an assessment of the efficacy
of CFTR-targeted molecular therapies.
However, even if this is done, the correlation
between changes in sweat chloride and lung
function in individuals with CF still may
not be apparent because of other variable
factors that affect lung function.
The Role of Testing Variability
Our results implicate the sweat test
procedure as an important source of
variability within a single clinical site. We
found that sweat chloride measurements
taken the same day on the same individual
varied by an average of 7.1 mmol/L. This
figure is similar to other reported estimates
(8.5 mmol/L in subjects with CF who had at
least one G551D mutation in CFTR) (38).
This variation is likely not unique to
individuals with CF, because studies of all
patients presenting for sweat chloride
testing found within-subject variability
ranging between 8.3 and 20.2% (median
coefficient of variation) (22, 39). Site-to-site
differences in measurement cause further
variation among individuals with identical
CFTR genotypes, particularly if different
techniques are used for measurement
(40, 41). Although testing variability
seems to be decreasing with time, revisiting
methods to standardize sweat testing
among centers could address this tractable
source of variation. Clinical studies may
need to consider adjusting for test center in
analyses to minimize this source of
variation.
Other Environmental Factors
Biologic factors that differ among
individuals, such as age or environmental
exposures, also contribute to variation. In
this study, age was associated with lower
sweat chloride values at younger ages,
suggesting that studies of molecular
therapies in young children could
underestimate treatment effect if sweat
chloride naturally increases with age (42).
Biologic variation in sweat chloride over
time has been observed in healthy
volunteers (n = 4), ranging from 14.2 to
32.8% over a 2-year period (43). Precision
and accuracy may be improved by
tackling these sources of variation by
reducing within-test-center variability
(as seems to be occurring over time) and
adjusting for biologic factors affecting
sweat chloride concentration, such as age,
and possibly, sex. Additionally, future
studies of potential sources of variation,
such as temperature and humidity, may
be helpful.
Study Population Influences
Although the patients enrolled in this study
are representative of the spectrum of CFTR
CF Twin-Sibling Study (n=1697)
Canadian Consortium (n=26)
French CF Study (n=44)
Dropped for:
Age at Sweat Unknown (n=14)
Discordant CFTR Genotypes (n=17)
Singletons (n=226)
Siblings dropped to yield "2
person families" (n=44)
Population for Heritability Analyses
604 families with 2 siblings (n=1208)
96 families with MZ twins (n=192)
30 families with DZ twins (n=60)
573 families with 2 siblings (n=1146)
90 families with MZ twins (n=180)
28 families with DZ twins (n=56)
29 families with 3 siblings (n=87)
6 families with MZ twins + Sib (n=18)
2 families with DZ twins + Sib (n=6)
1 family with 4 siblings (n=4)
1 family with 7 siblings (n=7)
Figure 4. Flow diagram for heritability analysis.
CF = cystic fibrosis; CFTR = cystic fibrosis
transmembrane conductance regulator;
DZ = dizygous; MZ =monozygous; Sib = sibling.
Table 3. Heritability Estimates Using Age-adjusted Sweat Chloride Measurements
Group n (Pairs)
Mean6 SD Sweat Chloride
Difference between Family Members Correlation (r)
Mean Heritability
Estimate (95% CI)*
All tests MZ twins 96 8.66 8.0 0.83 —
DZ twins 30 8.16 6.4 0.87 0 (0–0.35)
Siblings 604 13.96 12.2 0.52 0.60 (0.32–0.85)
Tests done on
the same day
MZ twins 56 8.46 8.3 0.86 —
DZ twins 16 7.16 5.5 0.90 0 (0–0.37)
Siblings 8 11.16 8.1 0.79 0.16 (0–0.91)
Definition of abbreviations: CI = confidence interval; DZ = dizygous; MZ =monozygous.
*Mean heritability estimates (with DZ twins or siblings compared with the MZ twins) and 95% CIs were calculated by bootstrapping 106 iterations with
random assignment of one twin/sibling as “A” and the other as “B.”
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dysfunction observed in CF, it should be
acknowledged that the subjects within the
CF Twin-Sibling Study, who comprised
most patients within this study, have better
lung function than individuals with CF
in the United States as reported to the
CF Foundation Patient Registry (13).
Underrepresentation of more severe disease
may underestimate the contribution of
CFTR if more severe disease is secondary to
underrepresented mutations within the
study population or overestimate the
contribution of CFTR if more severe disease
is a function of specific environmental
factors. It is also possible that common
environmental effects may mask modest
effects of modifier genes (44). Furthermore,
the current methods do not allow us to
detect potential effects of modifier gene–
CFTR interactions, gene–environment
interactions, or intragenic CFTR modifiers.
We were unable to fully assess the
contribution of the shared (common)
environment because most subjects (95.9%)
were less than 18 years of age when tested
and thus presumably living in a shared
family environment. Given that our sweat
chloride data were measured in more than
100 CF centers in several countries over
several decades, it is not possible to correct
for testing variability by location or time.
Use of these clinically obtained sweat test
results to identify a correlation with age
could be biased if patients being tested at
older ages have different disease
characteristics than those being tested as
infants. Additionally, our adjustment for
sweat chloride measurements using the
age at the time of testing in a Phe508del
homozygous population may not be
appropriate for all CFTR genotypes;
previous work by Kirk and coworkers
(45) demonstrated no change in sweat
chloride values at different ages in
children less than 12 years old with CF
and a linear decline in children greater
than or equal to 12 years of age and
adults.
Consequences for Sweat Chloride as
Biomarker
Our study suggests that most variation
(56.1%) in sweat chloride measurements
within the population of patients with CF is
a function of CFTR genotype. Thus, sweat
chloride may be better in terms of following
an individual subject’s response to CFTR
correctors and potentiators than lung
function or nutritional outcomes because
sweat chloride is not subject to progressive
decline and perhaps less subject to other
external factors (13–15, 46, 47). Individual
variation seems to be caused by
residual/random factors (41.9%), of which
we would speculate is largely caused by
testing variability on the same day, and
variability over time (58.1%), such as
different methods of measurement or
testing operators. To maximize the use of
sweat chloride as an outcome
measurement, testing variability should
be minimized with close attention to
standardization, and averaging multiple
independent sweat chloride measurements
preintervention and postintervention
could be considered. Studies should be
appropriately powered with the knowledge
that sweat chloride measurements vary on
average 7.6 mmol/L for measurements
obtained in the same person on the same
day and an additional 9.0 mmol/L in a
given individual over time based on our
mixed model. Alternatively, newer methods
of sweat testing could be considered (40).
Ultimately, if testing precision and accuracy
can be improved, perhaps first in a research
setting, sweat chloride could be a key
biomarker for individualized CF medicine,
where large randomized controlled trials
may not be possible to assess the effect
of therapies for less common CFTR
mutations. n
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